A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

Efficacy And Safety Of Ziprasidone In Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder, Including Patients With A Diagnosis Of Recent Onset

The purpose of this study is to evaluate the efficacy and safety of ziprasidone in acute exacerbation of schizophrenia or schizoaffective disorder, including patients with recent onset of symptoms

The study was prematurely discontinued due to the difficulty of subject recruitment on March 24, 2005. There were no safety concerns that led to the decision to terminate.

Inclusion Criteria:

• Patients not currently being treated with antipsychotic medication and neuroleptic naive patients
• Diagnosis of schizophrenia or schizoaffective disorder
• Antipsychotic treatment prior to screening was to be for a cumulative period of less than 5 years

Exclusion Criteria:

• Patients at immediate risk of committing harm to self or others
• Treatment with clozapine within 3 months prior to baseline
• History of neuroleptic treatment
• Current antipsychotic treatment